Celsion (CLSN) Receives DMC Approval to Continue ThermoDox Phase 3 Enrollment
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/25/2024
- Wall St drops as Meta Platforms, economic data weigh
- Q1 US GDP shows surprise slowing and uncomfortable inflation
- Meta shares dip on softer Q2 revenue guidance, elevated AI spending plans
- Oil steady as US demand concerns balance Middle East conflict risks
- Dollar firmer on higher U.S. inflation; yen sinks vs euro, US currency
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Hasbro (HAS) brand strength sees earnings top expectations
- Meta Platforms (META) Tops Q1 EPS by 39c, Offers Guidance
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Rubrik (RBRK) Prices Upsized 23.5M Share IPO at $32/sh
- Meta Platforms, IBM, Caterpillar fall premarket; American Airlines, Chipotle rise
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
Celsion's (CLSN) Phase 1b OVATION Study Receives Positive IDSMB Safety Review
December 1, 2016 8:05 AM ESTCelsion Corporation (Nasdaq: CLSN) announced that the independent Data Safety Monitoring Board (DSMB) has completed its safety review of data from the first four patient cohorts in the ongoing Phase 1b OVATION Study. Based on the DSMBs recommendation, the study will continue as planned and the Company will proceed with completing dosing in the fourth and final patient cohort, which is currently enrolling patients. The OVATION Study is a dose-escalating clinical trial combining GEN-1, the Company's DNA-based immunotherapy, with the standard of care for the treatment of newly-diagnosed patients with advanced ovarian cancer who will... More
